IR@PKUHSC  > 北京大学公共卫生学院
学科主题公共卫生
Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Sun, Feng1,2,3; Chai, Sanbao4; Yu, Kai5; Quan, Xiaochi1; Yang, Zhirong1; Wu, Shanshan1; Zhang, Yuan1; Ji, Linong6; Wang, Jun4; Shi, Luwen3
刊名DIABETES TECHNOLOGY & THERAPEUTICS
2015
DOI10.1089/dia.2014.0188
17期:1页:35-42
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Endocrinology & Metabolism
资助者National Natural Science Foundation of China ; Beijing Natural Science Foundation ; Research Fund for the Doctoral Program of Higher Education ; Doctoral Fund of Corps ; National Natural Science Foundation of China ; Beijing Natural Science Foundation ; Research Fund for the Doctoral Program of Higher Education ; Doctoral Fund of Corps
研究领域[WOS]Endocrinology & Metabolism
关键词[WOS]RANDOMIZED CLINICAL-TRIALS ; IMPROVES GLYCEMIC CONTROL ; DOUBLE-BLIND ; PARALLEL-GROUP ; OPEN-LABEL ; EXENATIDE ; EFFICACY ; MELLITUS ; SAFETY ; LIRAGLUTIDE
英文摘要

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a new class of drugs used in the treatment of type 2 diabetes mellitus (T2DM). Gastrointestinal (GI) adverse events (AEs) are the most frequently reported treatment-related AEs for GLP-1 RAs. We aim to evaluate the effect of GLP-1 RAs on the incidence of GI AEs of T2DM.

Materials and Methods: The overview of the GI events of GLP-1 RAs has been performed on relevant publications through the literature search, such as MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov The manufacturer was contacted regarding unpublished data. We analyzed direct and indirect comparisons of different treatments using Bayesian network meta-analysis.

Results: Taspoglutide 30 mg once weekly (TAS30QW) and lixisenatide 30 mu g twice daily (LIX30BID) were ranked the top two drugs in terms of GI AEs versus placebo. The odds ratios of nausea and vomiting for TAS30QW were 11.8 (95% confidence interval [CI], 2.89, 46.9) and 51.7 (95% CI, 7.07, 415), respectively, and that of diarrhea was 4.93 (95% CI, 1.75, 14.7) for LIX30BID.

Conclusions: Our study found all GLP-1 RA dose regimens significantly increased the incidence of GI AEs, compared with placebo or conventional treatment. The occurrence of GI AEs was different with diverse dose regimens of GLP-1 RAs. TAS30QW had the maximum probability to occur nausea and vomiting, whereas LIX30BID had the maximum probability to cause development of diarrhea versus other treatments.

语种英语
所属项目编号81302508 ; 81370152 ; 81228001 ; 7142027 ; 20120001110015 ; 2010JC15
资助者National Natural Science Foundation of China ; Beijing Natural Science Foundation ; Research Fund for the Doctoral Program of Higher Education ; Doctoral Fund of Corps ; National Natural Science Foundation of China ; Beijing Natural Science Foundation ; Research Fund for the Doctoral Program of Higher Education ; Doctoral Fund of Corps
WOS记录号WOS:000347538900006
引用统计
被引频次:16[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58278
专题北京大学公共卫生学院
作者单位1.Tianjin Fifth Cent Hosp, Dept Orthoped, Tianjin, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China
3.Shihezi Univ, Coll Med, Dept Prevent Med, Shihezi, Peoples R China
4.Peking Univ, Int Res Ctr Med Adm, Beijing 100871, Peoples R China
5.Capital Med Univ, Dept Physiol, Beijing 100069, Peoples R China
6.Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Sun, Feng,Chai, Sanbao,Yu, Kai,et al. Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis[J]. DIABETES TECHNOLOGY & THERAPEUTICS,2015,17(1):35-42.
APA Sun, Feng.,Chai, Sanbao.,Yu, Kai.,Quan, Xiaochi.,Yang, Zhirong.,...&Shi, Luwen.(2015).Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.DIABETES TECHNOLOGY & THERAPEUTICS,17(1),35-42.
MLA Sun, Feng,et al."Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis".DIABETES TECHNOLOGY & THERAPEUTICS 17.1(2015):35-42.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Sun, Feng]的文章
[Chai, Sanbao]的文章
[Yu, Kai]的文章
百度学术
百度学术中相似的文章
[Sun, Feng]的文章
[Chai, Sanbao]的文章
[Yu, Kai]的文章
必应学术
必应学术中相似的文章
[Sun, Feng]的文章
[Chai, Sanbao]的文章
[Yu, Kai]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。